Compounds useful for the treatment of obesity, type II diabetes and CNS disorders

(19)

(11)

EP 1 897 881 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A2)

(48)	Corrigendum issued on:
	11.08.2010 Bulletin 2010/32

(88)	Date of publication A3:
	18.03.2009 Bulletin 2009/12

(43)	Date of publication:
	12.03.2008 Bulletin 2008/11

(21)	Application number: 07122274.9

(22)	Date of filing: 19.06.2003

(51)

International Patent Classification (IPC):

C07D 471/04^(2006.01)
A61P 3/00^(2006.01)

C07D 495/04^(2006.01)
A61K 31/4365^(2006.01)

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
	Designated Extension States:
	LV

(30)

Priority:

20.06.2002 SE 0201925
11.07.2002 SE 0202181
26.08.2002 US 406120 P
01.10.2002 SE 0202908
17.12.2002 US 434010 P
10.02.2003 SE 0300357
23.04.2003 US 464701 P

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	03760999.7 / 1513828

(71)	Applicant: Biovitrum AB (publ)
	112 76 Stockholm (SE)

(72)	Inventors:
	Johansson, Gary 169 66, SOLNA (SE) Jenmalm Jensen, Annika 756 45, UPPSALA (SE) Beierlein, Katarina 756 55, UPPSALA (SE)


	Remarks:
	This application was filed on 04-12-2007 as a divisional application to the application mentioned under INID code 62.

(54)	Compounds useful for the treatment of obesity, type II diabetes and CNS disorders

(57) The present invention relates to compounds of the general formula (I),

wherein P is sulfone or sulfonamide; and
A, B, W, X, Y and R³ are as defined in the description;
to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders, to achieve reduction of body weight and of body weight gain.